Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value

1. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 1

   The volume of the cancer on three-dimensional measurement before and after treatment with neoadjuvant letrozole in combination with palbociclib. Each line represents the data for individual patient.
2. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 2

   (A) Overall change in Ki67 before and after treatment with neoadjuvant letrozole in combination with palbociclib. Each line represents the data for individual patient. Ki67 >15% was considered as high proliferation fraction. (B) Change in Ki67 before treatment, on day 15 and after treatment with neoadjuvant letrozole in combination with palbociclib. Each line represents the data for individual patient. Ki67 >15% was considered as high proliferation fraction.
3. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 3

   Change in relative gene expression level (dCt) of gene of interest. Each level represents the data for each individual patient.
4. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 4

   Change in EP score before and after treatment with neoadjuvant letrozole in combination with palbociclib. Each line represents the data for individual patient. EP score <5 was classified as low risk for distance recurrence; EP score ≥5 was stratified as high risk. EP, EndoPredict.
5. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 5

   Distribution of PEPI scores. A PEPI score of 0 predicts a low risk of recurrence; a score of 1–3 predicts an intermediate risk of recurrence; a score of 4 or higher predicts a high risk of recurrence. BCSS, breast cancer-specific survival; PEPI, preoperative endocrine prognostic index; RFS, relapse-free survival.
6. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 6

   Distribution of EPclin scores. EPclin score <3.3 was classified as low risk for distance recurrence; EPclin score ≥3.3 was stratified as high risk. EPclin, EndoPredict-clin.
7. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 7

   Neutropenia during the course of treatment. AE, adverse events.

• © 2018 The authors